NeuroBo Pharmaceuticals Advances Phase 2a Trial for DA-1241
NeuroBo Pharmaceuticals, Inc. is making significant strides in its clinical development efforts. This clinical-stage biotechnology company has recently announced a major milestone with the completion of the last patient’s visit in its two-part, Phase 2a clinical trial, which evaluates the efficacy and safety of DA-1241. This investigational drug targets metabolic dysfunction-associated steatohepatitis (MASH) through a novel mechanism as a G-Protein-Coupled Receptor 119 (GPR119) agonist.
DA-1241 and Its Clinical Significance
The completion of patient dosing in this trial is particularly significant as it brings NeuroBo one step closer to a topline data readout expected soon. The data will provide insights into the drug’s comparative efficacy against both placebo and in combination with sitagliptin, a DPP-4 inhibitor, which may enhance therapeutic outcomes.
Understanding the Mechanism of DA-1241
DA-1241’s mechanism involves the stimulation of GPR119, leading to the release of crucial gut peptides such as GLP-1, GIP, and PYY. These peptides are critical for improving glucose metabolism and lipid profiles, potentially offering a new solution for those facing challenges related to MASH. Previous Phase 1 studies suggested that DA-1241 is well tolerated, further reinforcing its promise as a therapeutic option.
Design of the Phase 2a Clinical Trial
The Phase 2a trial is structured into two separate components, both designed as multicenter, randomized, double-blind, placebo-controlled studies. Each part spans 16 weeks and includes a diverse group of patients diagnosed with presumed MASH. Out of 109 randomized patients, 95 completed the treatment regimen, which included DA-1241 administered at varying doses depending on the trial part.
Endpoints and Expectations
The primary endpoint of both parts is to assess the change in alanine transaminase (ALT) levels after 16 weeks of treatment. Secondary endpoints delve into cholesterol profiles, triglyceride levels, and other metabolic markers, raising hopes for comprehensive data supporting DA-1241's efficacy and safety.
About NeuroBo Pharmaceuticals
Founded with a dedication to transforming cardiometabolic diseases, NeuroBo Pharmaceuticals is also working on DA-1726, another innovative drug targeting obesity. DA-1241 is pivotal as it approaches its final evaluation in the clinical pathway for MASH treatment.
In addition to its therapeutic targets, NeuroBo's commitment extends to demonstrating the potential benefits of DA-1241 in various preclinical studies. These studies have indicated that it not only improves liver health but also positively affects glucose control and lipid metabolism.
Looking Ahead
With the completion of key clinical milestones for DA-1241, NeuroBo Pharmaceuticals is poised to release critical data that may reshape the landscape of treating MASH. Stakeholders eagerly await the trial results that could pave the way for possible future approvals and therapeutic approaches in managing this complex metabolic disorder.
Frequently Asked Questions
What is the purpose of the Phase 2a trial for DA-1241?
The Phase 2a trial aims to evaluate the efficacy and safety of DA-1241 in patients with metabolic dysfunction-associated steatohepatitis (MASH).
How many patients were involved in the trial?
a total of 109 patients were randomized, with 95 completing the dosing for the two-part clinical trial.
What outcomes are being monitored in this trial?
The primary outcome involves measuring changes in alanine transaminase (ALT) levels, while secondary outcomes include cholesterol levels and other metabolic indicators.
Who is the leading figure at NeuroBo Pharmaceuticals?
Hyung Heon Kim serves as the President and Chief Executive Officer of NeuroBo Pharmaceuticals, overseeing the company's strategic direction.
Where can I find more information about the clinical trial?
More details can be accessed through clinical trial registries or NeuroBo's official communications.
